ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception
{{output}}
Endocrine resistance in estrogen receptor-positive (ER+) breast cancer has undergone a fundamental reconceptualization over the past decade. The discovery that activating mutations in the ESR1 gene encoding ERα emerge under aromatase inhibitor (AI) selection ... ...
